Follow the latest coverage, related explainers and connected technology stories.
A study funded by Dexcom and published in the New England Journal of Medicine found that using the Dexcom G7 improved HbA1c levels and time in the target range among people with type 2 diabetes who do not use insulin. The findings come as Dexcom awaits a decision from CMS on expanding Medicare coverage for these devices.
Dexcom and Abbott are awaiting a CMS decision that could expand Medicare coverage for continuous glucose monitoring devices to include patients with type 2 diabetes who do not use insulin. Dexcom expects the decision before the end of 2026, with potential coverage beginning in mid-2027.